



## Skyepharma Strengthens Its Position in Oncology Development & Manufacturing With Fully Operational Facility in France

**Saint-Quentin-Fallavier, France – May 2025**

Six months after inaugurating its state-of-the-art development & production facility for highly potent oral oncology drugs, Skyepharma is proud to share key achievements and the growing impact of its MMPP area (*"Médicaments à Manipuler avec des Précautions Particulières", Medicines to be Handled with Particular Care*). "The facility is one of France's leading development & production hubs for high-potency oral anticancer treatments and plays a strategic role in the relocation of essential medicines."

The 450 m<sup>2</sup> MMPP area is fully equipped for the handling of cytotoxic and cytostatic compounds up to OEB4/5+ safety standards. With its GMP-compliant containment systems and specialized labs, Skyepharma offers production capacity exceeding 80 million tablets and 200 million capsules per year.

*"Today, we are fully equipped to contribute to the development of innovative treatments for oncological diseases. Moreover, by reshoring strategic medicines to French territory, we aim to play a key role in mitigating the risks of shortages,"* said David LESCUYER, President of Skyepharma. — *"We are proud of this achievement and are determined to continue developing new projects in this direction — to meet patient needs and contribute to public health improvement."*

### Results Since Launch

- 4 industrial partnerships signed in the oncology field, including scale-up and commercial production
- 15 highly skilled jobs created to support production, quality, and R&D functions
- Recognition as one of the few French CDMOs able to handle HPAPIs for oral anticancer treatments
- A projected annual revenue of €10 million from oncology-related activities.

### Why This Facility Matters Now

Skyepharma's MMPP unit offers a rare, robust, and local solution — with:

- Advanced containment & GMP compliance
- Full integration with formulation, analytics, packaging & regulatory support
- Dedicated expertise in small batch, high-value manufacturing for biotech and specialty pharma

This project received partial funding through the France Relance program, reinforcing national and European objectives for health resilience.

### **A Strategic Shift with Long-Term Vision**

Skyepharma's investment in the MMPP area is more than infrastructure — it reflects a strategic direction. The company is reinforcing its role as a critical enabler of oncology innovation, offering specialized services from development to commercial production.

Skyepharma continues to support clients across the full lifecycle of oral complex drugs, with proprietary delivery platforms such as Geoclock™, SOCTEC®, Nanomics, Geomatix, and Mucotabs — and with Skyehub®, a dedicated program to accelerate biomedicine industrialization.



**Watch the video:** [Skyepharma HPAPI Area – Immuno-Oncology](#)

**For more information, please contact:**

**Laura Castillo – Communication Assistant – Skyepharma**

Phone: +33 (0)4 74 95 21 78

Email: [l.castillo@skyepharma.fr](mailto:l.castillo@skyepharma.fr)

Website: [www.skyepharma.com](http://www.skyepharma.com)